lawsuit against semaglutide 🚨 A major just escalated pressure on compounded GLP-1s in Med Spas Last week, Novo Nordisk filed suit telehealth company Hims & Hers over compounded products, signaling intensifying legal Ozempic Class Action Lawsuit: Protect

Ikotun, A

Novo Nordisk vs Eli Lilly: The GLP-1 Battle Two trillion-dollar companies

Retatrutide Clinical Research Findings The clinical development program for retatrutide has produced compelling data across multiple research endpoints: Weight Loss Efficacy: Phase 2 trials showed dose-dependent weight reduction ranging from 8.7% at the lowest dose to 24.2% at the highest dose over 48 weeks Metabolic Improvements: Participants demonstrated improvements in glycemic control, lipid profiles, and blood pressure measurements Safety Profile: Gastrointestinal effects (nausea, vomiting, diarrhea) were the most common adverse events, occurring in 60-80% of participants but generally rated as mild to moderate in severity Sustained Effects: Weight loss continued throughout the trial period without evidence of plateau, suggesting ongoing metabolic benefits These findings have positioned retatrutide as a leading candidate for advanced metabolic research

Designing Research Protocols With Retatrutide Good retatrutide protocol design starts before the first dose

Weeks 5 through 8: 0.1 mg once a week

Weight loss is a secondary effect